摘要
目的探讨瑞舒伐他汀对行PCI术后急性冠脉综合征(ACS)患者miR-155/SHIP-1信号通路及心血管事件的影响。方法选取我院行PCI的急性冠脉综合征患者181例,所有患者随机分为对照组(91例,给予等量生理盐水)和瑞舒伐他汀组(90例,PCI术前12 h、2 h分别给予20 mg瑞舒伐他汀),记录临床基线资料。分别于术前及PCI术后24 h取外周血,检测c Tn I、IFN-γ、TNF-α、IL-6水平,以及血清miR-155和外周血单核细胞SHIP-1的mRNA表达,检测调节性T细胞(CD4^+Foxp3^+T)。术后30 d对患者进行随访,记录出现的严重心血管不良事件。结果与对照组比较,瑞舒伐他汀组患者c Tn I、IFN-γ、TNF-α、IL-6和血清miR-155的表达显著降低,SHIP-1的mRNA相对表达量及CD4^+Fox P3^+Treg比例增加(P<0.05)。瑞舒伐他汀组患者术后30 d的严重心血管意外事件少于对照组,差异有统计学意义(P<0.05)。结论 PCI术前使用负荷剂量瑞舒伐他汀能够降低ACS患者心血管事件的发生率,其机制可能与抑制miR-155/SHIP-1信号通路活性相关。
Objective To investigate the effect of rosuvastatin on cardiovascular events and miR-155/SHIP-1signaling pathway in patients with acute coronary syndrome（ACS） undergoing percutaneous coronary intervention.Methods Patients with ACS undergoing PCI（n = 181） were randomized into control group（NS treatment,n =91）and rosuvastatin group（rosuvastatin 20 mg was given at 2 h and 12 h before PCI,n =90）,and the baseline data of the patients was recorded.Levels of INF-γ,TNF-α,IL-6,miR-155 /SHIP-1 and CD4~＋ FoxP3~＋Treg in peripheral blood were detected before PCI and at 24 h after PCI.The severe cardiovascular events were recorded at 30 d after PCI.Results Compared with control group,the levels of cardiac troponin-I（cTnI）,INF-γ,TNF-α and IL-6 and the expression of miR-155 in rosuvastatin group decreased（P〈0.05）,but SHIP-1 mRNA expression and CD4~＋FoxP3~＋Treg proportion increased（P〈0.05）.The rate of severe cardiovascular event in patients of rosuvastatin group was lower than that of control group（P〈0.05）.Conclusion The loading-dose rosuvastatin pretreatment can reduce the incidence of cardiovascular events and the levels of inflammatory markers in patients with ACS undergoing PCI,which may be related to the suppression of miR-155/SHIP-1 signaling pathway.
出处
《实用药物与临床》
CAS
2016年第6期670-673,共4页
Practical Pharmacy and Clinical Remedies
基金
广西科学研究与技术开发计划(桂科攻1598012-4)
玉林市科学研究与技术开发计划(玉科计20141002)
